The Company is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Recently had a slight setback with their drug Acurox, FDA rejected it but there is still a chance that it will get passed if the regulator says its ok. Right now they plan on submitting a new application in early 2011 with a new version of the drug that will have much better odds of getting approved. This company might not have much growth short term, but in the long term should be very profitable. They have a large number of drugs which should boost numbers in the next couple of years. Also a court ruling is causing one of the generic competitors Skelaxin off the market for now.